<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867295</url>
  </required_header>
  <id_info>
    <org_study_id>2009/22</org_study_id>
    <nct_id>NCT00867295</nct_id>
  </id_info>
  <brief_title>Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device</brief_title>
  <acronym>TIVAD</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial to Determine Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial is determining the role of antibiotic prophylaxis in the prevention of
      the infectious complications in patients carrying out totally implantable venous access
      device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>infectious complication</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no antibiotic is used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefazolin Sodium 1g i.v. before the operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefazolin Sodium</intervention_name>
    <description>cefazolin Sodium 1g i.v. before operation</description>
    <arm_group_label>drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years of age

          -  Have solid tumor

          -  White cells &gt;4000

          -  Platelets &gt;100.000

          -  Prothrombin time in normal range

        Exclusion Criteria:

          -  Drug allergy

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Karanlik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Institute of Oncology Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul University Institute of Oncology</name>
      <address>
        <city>Istanbul</city>
        <state>Capa</state>
        <zip>34190</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Istanbul University Institute of Oncology (Hasan Karanlik, MD)</name_title>
    <organization>Istanbul University Institute of Oncology</organization>
  </responsible_party>
  <keyword>implantable catheters</keyword>
  <keyword>Indwelling Catheters</keyword>
  <keyword>infection</keyword>
  <keyword>cefazolin sodium</keyword>
  <keyword>prophylactic</keyword>
  <keyword>antibiotic</keyword>
  <keyword>totally implantable venous access device</keyword>
  <keyword>cancer patients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

